R&D News | pharmaphorum

News

GSK has said it will file its oral carbapenem antibiotic tebipenem HBr for approval before the end of this year as a treatment for complicated UTIs.

News

InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.

News

Teva gets fast-track status from the FDA for a coeliac disease drug with a mechanism that has proved tough to crack.

News

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

News

For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.

News

Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance.